ORGO (Organogenesis Holdings) 3-Year RORE % : 69.75% (As of Mar. 2026)


ORGO Organogenesis Holdings Inc ORGO
67 GF Score
Price $2.36
GF Value $3.10
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Organogenesis Holdings 3-Year RORE %?

Organogenesis Holdings ORGO -3.08% 67 3-Year RORE % is 69.75 as of Mar. 2026. GuruFocus rates ORGO with a GF Score™ of 67/100 and a GF Value™ of $3.10 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 936 Drug Manufacturers companies, Organogenesis Holdings ranks better than 87.18% on this metric.

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. Organogenesis Holdings's 3-Year RORE % for the quarter that ended in Mar. 2026 was 69.75%.

The industry rank for Organogenesis Holdings's 3-Year RORE % or its related term are showing as below:

ORGO's 3-Year RORE % is ranked better than
87.18% of 936 companies
in the Drug Manufacturers industry
Industry Median: 3.075 vs ORGO: 69.75

Organogenesis Holdings  (NAS:ORGO) 3-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


Organogenesis Holdings 3-Year RORE % Related Terms


Organogenesis Holdings 3-Year RORE % Historical Data

* Premium members only.

The historical data trend for Organogenesis Holdings's 3-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Organogenesis Holdings 3-Year RORE % Chart

Organogenesis Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
3-Year RORE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 292.31 -0.84 -77.39 -102.90 45.83

Organogenesis Holdings Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
3-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,281.82 115.63 261.90 45.83 69.75

ORGO vs TKNO, AKBA, SIGA: 3-Year RORE % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Organogenesis Holdings's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Organogenesis Holdings 3-Year RORE % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Organogenesis Holdings's 3-Year RORE % distribution charts can be found below:

* The bar in red indicates where Organogenesis Holdings's 3-Year RORE % falls into.


ORGO
67GF Score
Organogenesis Holdings Inc ORGO
3-Year RORE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Organogenesis Holdings 3-Year RORE % Calculation

Organogenesis Holdings's 3-Year RORE % for the quarter that ended in Mar. 2026 is calculated as:

3-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 3-year -Cumulative Dividends per Share for 3-year )
=( -0.19-0.036 )/( -0.324-0 )
=-0.226/-0.324
=69.75 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2026 and 3-year before.

Frequently Asked Questions Learn more about 3-Year RORE % →
What does a 3-Year RORE % of 69.75 mean?
Organogenesis Holdings (ORGO) has a 3-Year RORE % of 69.75 as of Mar. 2026. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Organogenesis Holdings and its competitors. According to the industry distribution chart, Organogenesis Holdings ranks #120 out of 936 companies in the Drug Manufacturers industry, placing it in the top 12.8%.
Is Organogenesis Holdings' 3-Year RORE % too high?
Organogenesis Holdings' current 3-Year RORE % is 69.75. The Drug Manufacturers industry median 3-Year RORE % is 3.08. Organogenesis Holdings' value of 69.75 is 2168.3% above this industry median. Based on the distribution chart, Organogenesis Holdings ranks #120 out of 936 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Organogenesis Holdings has a GF Score™ of 67/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Organogenesis Holdings' 3-Year RORE % compare to TKNO and AKBA?
According to the Drug Manufacturers industry distribution chart, Organogenesis Holdings ranks #120 out of 936 companies for 3-Year RORE %. This places Organogenesis Holdings in the top 13% of its industry — outperforming the majority of peers. The industry median 3-Year RORE % is 3.08. Organogenesis Holdings' value of 69.75 is 2168.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Drug Manufacturers company?
The median 3-Year RORE % among Drug Manufacturers companies is 3.08, based on 936 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year RORE % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Organogenesis Holdings's current 3-Year RORE % of 69.75 is 2168.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Organogenesis Holdings and its competitors. For the Drug Manufacturers industry, the median 3-Year RORE % is 3.08 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Organogenesis Holdings's current 3-Year RORE % is 69.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Organogenesis Holdings stock overvalued right now?
Based on GuruFocus' analysis, Organogenesis Holdings (ORGO) is currently considered Modestly Undervalued. The stock's GF Value™ is $3.10, compared to a current price of $2.36 — trading 23.9% below its estimated fair value. The current 3-Year RORE % is 69.75 and 2168.3% above the Drug Manufacturers industry median of 3.08. Organogenesis Holdings' overall GF Score™ is 67/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Organogenesis Holdings (ORGO), the current 3-Year RORE % is 69.75 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Organogenesis Holdings (ORGO) Overvalued in 2026?

Based on GuruFocus' analysis, Organogenesis Holdings stock appears to be undervalued. The current stock price of $2.36 is trading 23.9% below its estimated GF Value™ of $3.10. GuruFocus considers Organogenesis Holdings to be Modestly Undervalued.

Key valuation signals for ORGO:

  • 3-Year RORE %: 69.75
  • GF Value™: $3.10 vs. price of $2.36 (23.9% below fair value)
  • GF Score™: 67/100 with 5 warning signs
  • Industry Position: 2168.3% above the Drug Manufacturers median (#120 of 936)

No single metric tells the full story. See the ORGO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Organogenesis Holdings Business Description

Other Exchanges 2PQ:Germany
Address 85 Dan Road, Canton, MA, USA, 02021
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.
67GF Score

Get the complete analysis for ORGO

3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.36
Price
$3.10
GF Value